Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy

Journal of Medical Virology

Volumn 79, Issue 8, 2007, Pages 1040-1046

  Poveda, Eva ^a   Briz, Verónica ^a   De Mendoza, Carmen ^a   Benito, José Miguel ^a   Corral, Angélica ^a   Zahonero, Natalia ^a   Lozano, Sara ^a   González Lahoz, Juan ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Co receptor antagonists; HIV tropism; Pathogenesis

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; INTERLEUKIN 7; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COMPUTER PROGRAM; DRUG EXPOSURE; DRUG TREATMENT FAILURE; FEMALE; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PROTEIN BLOOD LEVEL; SEQUENCE ANALYSIS; SEROCONVERSION; SPAIN; VIRUS LOAD; VIRUS PATHOGENESIS;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INTERLEUKIN-7; MALE; RECEPTORS, CELL SURFACE; RETROSPECTIVE STUDIES; RNA, VIRAL; VARIATION (GENETICS);

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34347361504     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20900     Document Type: Article

References (47)

1. Berger E, Doms R, Fenyö E, Korber B, Littman D, Moore J, Sattentau Q, Schuitemaker H, Spdroski J, Weiss R. 1998. A new classification for HIV-1. Nature 391:240.
2. Brenchley J, Schacker T, Ruff L, Price D, Taylor J, Beilman G, Nguyen P, Khoruts A, Larson M, Haase A, Douek D. 2004. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 200:749-759.
3. Briz V, Poveda E, Soriano V. 2006. HIV entry inhibitors: Mechanisms of action and resistance pathways. J Antimicrob Chemother 57:619-627.
4. Brumme Z, Goodrich J, Mayer H, Brumme C, Henrick B, Wynhoven B, Asselin J, Cheung P, Hogg R, Montaner J, Harrigan P. 2005. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 192:466-474.
5. Correa R, Munoz-Fernandez MA. 2001. Viral phenotype affects the thymic production of new T cells in HIV-1-infected children. AIDS 15:1959-1963.
6. Correa R, Resino S, Munoz-Fernandez MA. 2003. Increased interleukin-7 plasma levels are associated with recovery of CD4+ T cells in HIV-infected children. J Clin Immunol 23:401-406.
7. De Mendoza C, Rodriguez C, Colomina J, Tuset C, Garcia F, Eiros JM, Corral A, Leiva P, Aguero J, Torre-Cisneros J, Pedreira J, Viciana I, del Romero J, Saez A, Ortiz de Lejarazu R, Soriano V. 2005. Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain. Clin Infect Dis 41:1350-1354.
8. Deeks S, Wrin T, Liegler T, Hoh R, Hayden M, Barbour J, Hellmann N, Petropoulos C, McCune J, Hellerstein M. 2001. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 344:472-480.
9. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666.
10. Dragic T, Litwin V, Allaway G, Martin S, Huang Y, Nagashima K, Cayanan C, Maddon P, Koup R, Moore J, Paxton W. 1996. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673.
11. Feng Y, Broder C, Kennedy P, Berger E. 1996. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272:872-877.
12. Garrido C, Chueca N, Aguilera A, Skrabal K, Poveda E, Zahonero N, Carlos S, Garcia F, Faudon JL, de Mendoza, Soriano V. 2007. Prevalence of X4 viruses in patients infected with HIV-1 non-B subtypes. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA. Abstract D-171.
13. Holtkamp N, Otteken A, Findhammer S, Miller V, Kurth R, Werner A. 2000. Unexpected coreceptor usage of primary human immunodeficiency virus type 1 isolates from viremic patients under highly active antiretroviral therapy. J Infect Dis 181:513-521.
14. Hunt P, Harrigan P, Huang W, Bates M, Williamson D, McCune J, Price R, Spudich S, Lampiris H, Hoh R, Leigler T, Martin J, Deeks S. 2006. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis 194:926-930.
15. Jenkis M, Khoruts A, Ingulli E, Mueller D, McSorley S, Reinhardt R, Itano A, Pape K. 2001. In vivo activation of antigen-specific CD4 T cells. Annu Rev Immunol 19:23-45.
16. Jensen M, vańt Wout A. 2003. Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev 5:104-112.
17. Johnson V, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes D, Pillay D, Schapiro J, Rtichman D. 2005. Update of the drug resistance mutations in HIV-1: Fall 2005. Topics HIV Med 13:125-131.
18. Kawamura T, Kurtz S, Blauvelt A, Shimada S. 2005. The role of Langerhans cells in the sexual transmission of HIV. J Dermatol Sci 40:147-155.
19. Koot M, Keet I, Vos A, de Goede R, Roos M, Coutinho R. 1993. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 118:681-688.
20. Labernardiere J, Lebel-Binay S, Faudon JL, Holguin A, Soriano V, Cheret A. 2004. Tropism determination and performance of Phenoscript HIV-1 entry inhibitors assay. Antivir Ther 9:S141.
21. Lehmann C, Däumer M, Boussaad I, Sing T, Beerenwinkel N, Lengauer T, Schmeisser N, Wyen C, Fätkenheuer G, Kaiser R. 2006. Stable coreceptor usage of HIV in patients with ongoing treatment failure on HAART. J Clin Virol 37:300-304.
22. Lin Y, Portales P, Segondy M, Baillant V, Merle de Boever C, Le Moing V, Reant B, Montes B, Clot J, Reynes J, Corbeau P. 2005. CXCR4 overexpression during the course of HIV-1 infection correlates with the emergence of X4 strains. J Acquir Immune Defic Syndr 39:530-536.
23. Llano A, Barretina J, Gutiérrez A, Blanco J, Cabrera C, Clotet B, Este J. 2001. Interleukin-7 in plasma correlates with CD4 T cell depletion and may be associated with emergence of syncytium-inducing variants in HIV type 1-positive individuals. J Virol 75:10319-10325.
24. Low A, Skrabal K, Dong W, Mammano F, Sing T, Cheung P, Harrigan R. 2006. Is there a gold standard for determining HIV co-receptor usage in clinical samples? A comparison of two phenotypic assays and a bioinformatic model. 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO. Abstract 658.
25. Margolis M, Shattock R. 2006. Selective transmission of CCR5-utilizing HIV-1: The "gatekeeper" problem resolved? Nat Rev Microbiol 4:312-327.
26. Martinez-Picado J, Savara A, Shi L, Sutton L, D́Aquila R. 2000. Fitness of HIV type 1 protease inhibitor-selected single mutants. Virology 275:318-322.
27. Matroianni C, Forcina G, d'Etorre C, Lichtner M, Mengoni F, D́Agostino C, Vullo V. 2001. Circulating levels of interleukin-7 in antiretroviral-naive and highly active antiretroviral therapy-treated HIV-infected patients. HIV Clin Trials 2:108-112.
28. Mehandru S, Poles M, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, Boden D, Racz P, Markowitz M. 2004. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 200:761-770.
29. Moore J, Kitchen S, Pugach P, Zack J. 2004. The CCR5 and CXCR4 coreceptors - Central to understanding the transmission and pathogenesis of HIV type 1 infection. AIDS Res Hum Retroviruses 20:111-126.
30. Nicastri E, Sarmati L, d́Etorre G, Parisi S, Palmisano L, Galluzzo C, Montano M, Uccella I, Amici R, Gatti f, Vullo V, Concia E, Vella S, Andreoni M. 2003. High prevalence of M184 mutation among patients with viro-immunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis. J Clin Microbiol 41:3007-3012.
31. Nishimura Y, Brown C, Mattapallil J, Igarashi T, Buckler-White A, Lafont B, Hirsch V, Roederer M, Martin M. 2005. Resting naive CD4+ T cells are massively infected and eliminated by X4-tropic simian-human immunodeficiency viruses in macaques. Proc Natl Acad Sci USA 102:8000-8005.
32. Pillai S, Good B, Richman D, Corbeil J. 2003. A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses 19:145-149.
33. Pope M, Haase A. 2003. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med 9:847-852.
34. Poveda E, Rodés B, Toro C, Martín-Carbonero L, González-Lahoz J, Soriano V. 2002. Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor. AIDS 16: 1959-1961.
35. Poveda E, Briz V, Quinones-Mateu M, Soriano V. 2006. HIV tropism: Diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS 20:1359-1367.
36. Rathmell J, Farkash E, Gao W, Thompson C. 2001. IL-7 enhances the survival and maintains the size of naive T cells. J Immunol 167: 6869-6876.
37. Richman D, Bozzette S. 1994. The impact of the syncytium-inducing phenotype of HIV on disease progression. J Infect Dis 169:968-974.
38. Samson M, Libert F, Doranz B, Rucker J, Liesnard C, Farber C, Saragosti s, Lapoumeroulie c, Cognaux J, Forceille c, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth R, Collman R, Doms R, Vassart G, Parmentier M. 1996. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382:722-725.
39. Schuitemaker H, Koot M, Kootstra N, Dercksen M, de Goede R, van Steenwijk R, Schattenkerk J, Miedema F, Tersmette M. 1992. Biological phenotype of HIV type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations. J Virol 66:1354-1360.
40. Seibert C, Sakmar T. 2004. Small-molecule antagonists of CCR5 and CXC R4:A promising new class of anti-HIV drugs. Curr Pharm Des 10:2041-2062.
41. Spira A, Marx P, Patterson B, Mahoney J, Koup R, Wolinsky S, Ho D. 1996. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med 183:215-225.
42. Tersmette M, de Goede R, Al B, Winkel I, Gruters R, Cuypers H, Huisman H, Miedema F. 1988. Differential syncytium-inducing capacity of HIV isolates: Frequent detection of syncytium-inducing isolates in patients with AIDS and AIDS-related complex. J Virol 62:2026-2032.
43. Van Baelen K, Vandenbroucke I, Vermeiren H, Rondelez E, Van Eygen V, Stuyver L. 2006. Description of a new quantitative and qualitative tropism testing platform. 2nd International Workshop on Targeting Viral Entry, Boston, MA. Abstract 25.
44. Veaze R, DeMaria M, Chalifoux L, Shevetz D, Pauley D, Knight H, Rosenzweig M, Johnson R, Desrosiers R, Lackner A. 1998. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 280:427-431.
45. Watanabe M, Ueno Y, Yajima T, Iwao Y, Tsuchiya M, Ishikawa H, Aiso S, Hibi T, Ishii H. 1995. Interleukin 7 is produced by human intestinal epithelial cells and regulates the proliferation of intestinal mucosal lymphocytes. J Clin Invest 95:2945-2953.
46. Zaitseva M, Lee S, Rabin R, Tiffany H, Farber J, Peden K, Murphy P, Golding H. 1998. CXCR4 and CCR5 on human thymocytes: Biological function and role in HIV-1 infection. J Immunol 161:3103-3113.
47. Zhang Z, Schuler T, Zupancic M, Wietgrefe S, Staskus K, Reimann K, Reinhart T, Rogan M, Cavert W, Miller C, Veazey R, Notermans D, Little S, Danner S, Richman D, Havlir D, Wong J, Jordan H, Schacker T, Racz P, Tenner-Racz K, Letvin N, Wolinsky S, Haase A. 1999. Sexual transmission and propagation of simian and HIV in two distinguishable populations of CD4+ T cells. Science 286:1353-1357.